Ardelyx/$ARDX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Ardelyx
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. It product Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.
Ticker
$ARDX
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
395
ISIN
US0396971071
Website
Ardelyx Metrics
BasicAdvanced
$1.1B
-
-$0.23
0.76
-
Price and volume
Market cap
$1.1B
Beta
0.76
52-week high
$6.71
52-week low
$3.21
Average daily volume
4.8M
Financial strength
Current ratio
4.123
Quick ratio
3.434
Long term debt to equity
123.787
Total debt to equity
124.681
Interest coverage (TTM)
-1.78%
Profitability
EBITDA (TTM)
-37.391
Gross margin (TTM)
68.92%
Net profit margin (TTM)
-14.86%
Operating margin (TTM)
-10.95%
Effective tax rate (TTM)
-1.90%
Revenue per employee (TTM)
$920,000
Management effectiveness
Return on assets (TTM)
-6.58%
Return on equity (TTM)
-36.26%
Valuation
Price to revenue (TTM)
2.957
Price to book
7.42
Price to tangible book (TTM)
7.42
Price to free cash flow (TTM)
-21.948
Free cash flow yield (TTM)
-4.56%
Free cash flow per share (TTM)
-20.59%
Growth
Revenue change (TTM)
127.33%
Earnings per share change (TTM)
-22.03%
3-year revenue growth (CAGR)
349.48%
10-year revenue growth (CAGR)
28.72%
3-year earnings per share growth (CAGR)
-44.91%
10-year earnings per share growth (CAGR)
-6.07%
What the Analysts think about Ardelyx
Analyst ratings (Buy, Hold, Sell) for Ardelyx stock.
Bulls say / Bears say
Ardelyx reported significant commercial progress in 2024, achieving total revenue of $333.6 million, including $319.2 million in U.S. net product sales, indicating strong market acceptance of its products. (GlobeNewswire)
The company's lead product, tenapanor, has been approved by the FDA for the treatment of chronic kidney disease, expanding its market potential and addressing a significant unmet medical need. (The Motley Fool)
Institutional investors, such as State Street Corp, have increased their holdings in Ardelyx, reflecting confidence in the company's growth prospects. (MarketBeat)
Ardelyx reported a net loss in Q1 2025, missing revenue estimates by 8.14%, which may raise concerns about its financial stability. (ChartMill)
Insider selling activity, including CEO Michael Raab's sale of 41,666 shares, might signal a lack of confidence in the company's short-term prospects. (Defense World)
Analysts have reduced their price targets for Ardelyx, with Jefferies Financial Group lowering its price objective from $11.00 to $8.00, indicating tempered expectations for future performance. (Defense World)
Data summarised monthly by Lightyear AI. Last updated on 6 Jul 2025.
Ardelyx Financial Performance
Revenues and expenses
Ardelyx Earnings Performance
Company profitability
Ardelyx News
AllArticlesVideos
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ardelyx, Inc. - ARDX
GlobeNewsWire·4 weeks ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ardelyx, Inc. - ARDX
Accesswire·1 month ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ardelyx, Inc. - ARDX
Accesswire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Ardelyx stock?
Ardelyx (ARDX) has a market cap of $1.1B as of July 18, 2025.
What is the P/E ratio for Ardelyx stock?
The price to earnings (P/E) ratio for Ardelyx (ARDX) stock is 0 as of July 18, 2025.
Does Ardelyx stock pay dividends?
No, Ardelyx (ARDX) stock does not pay dividends to its shareholders as of July 18, 2025.
When is the next Ardelyx dividend payment date?
Ardelyx (ARDX) stock does not pay dividends to its shareholders.
What is the beta indicator for Ardelyx?
Ardelyx (ARDX) has a beta rating of 0.76. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.